AbbVie Inc. stock gains on dividend hike and strong Q2 2026 figures

Published on 09/15/2026 at 12:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AbbVie Inc. stock is trading near its recent highs after the company raised its quarterly dividend to USD 1.73 with a payment date in November 2026 and reported double-digit revenue growth in Q2 2026. The shares recently closed at USD 261.77 on September 14, 2026, supported by a Moderate Buy consensus and a price target around USD 276.

Fotorealistisches Pharma-Forschungslabor mit Petrischalen und Wissenschaftlern in Schutzkleidung — AbbVie Inc. US00287Y1091 fotorealistisches Pharma Forschungslabor mit Petrischalen Wissenschaftlern Immunologie Onkologie Biopharma, Illustration mit AI erstellt.

AbbVie Inc. stock (ISIN US00287Y1091) is trading close to its recent highs after the biopharmaceutical group reported solid second-quarter 2026 earnings and approved a higher quarterly dividend of USD 1.73 per share payable on November 16, 2026, reinforcing its income appeal for investors as of mid-September 2026.

Dividend increase underpins income profile

AbbVie, Inc. (NYSE: ABBV) has raised its quarterly cash dividend to USD 1.73 per share, with the payment scheduled for November 16, 2026 and the ex-dividend date set for October 15, 2026, according to TradingView on September 14, 2026.

The new dividend level implies an annualized payout of USD 6.92 per share and a dividend yield of roughly 2.6 percent based on recent share prices, as detailed by MarketBeat on September 15, 2026.

Q2 2026 earnings show double-digit revenue growth

For the second quarter of 2026, AbbVie reported earnings per share of USD 3.65, slightly above the analyst consensus of USD 3.61 by USD 0.04, according to MarketBeat in its summary of AbbVie’s latest quarterly earnings data published on September 15, 2026.

Revenue for the quarter amounted to USD 16.99 billion compared to analyst estimates of USD 16.80 billion, which represents an increase of 10.2 percent versus the same quarter a year earlier, as highlighted by MarketBeat.

The company posted a net margin of 9.80 percent in this quarter, reflecting improvements on a larger revenue base, while return on equity was reported at a negative 422.07 percent due to capital structure effects, according to the same overview by MarketBeat.

AbbVie has also issued guidance for the third quarter of 2026, projecting earnings per share in a range of USD 3.84 to USD 3.88, which sets a benchmark for investor expectations in the second half of the year, as reported by MarketBeat.

Analyst sentiment and institutional interest support the stock

Analyst coverage remains supportive: 25 of 31 Wall Street analysts following AbbVie rate the shares a buy, and the average price target stands around USD 277 per share, above the current trading level, according to Yahoo Finance in an article dated September 15, 2026.

A separate overview shows that the consensus rating on AbbVie is classified as Moderate Buy with an average price target of USD 276.64, reinforcing the broadly positive stance among research houses, as summarized by MarketBeat on September 15, 2026.

Institutional investors have been active in the stock as well: a recent disclosure indicates that Bank of America Corp DE holds a position of USD 5.34 billion in AbbVie, illustrating the scale of institutional exposure to the company, according to MarketBeat.

Another filing shows that National Pension Service acquired 59,876 AbbVie shares, underlining ongoing demand from long-term institutional holders, as reported by MarketBeat on September 15, 2026.

Hedge fund activity also supports the story: billionaire investor Ken Griffin’s Citadel significantly increased its AbbVie stake by over 500 percent in the second quarter of 2026, highlighting confidence in the company’s cash flows and dividend profile, according to Yahoo Finance on September 15, 2026.

Pipeline investments and oncology progress

The dividend decision is linked to AbbVie’s broader capital allocation strategy, which balances shareholder returns with investment in its research and development pipeline, especially in oncology and neuroscience, as outlined by TradingView.

AbbVie is advancing several Phase III oncology programs, which are expected to support long-term growth and partly offset the impact of patent expirations in its legacy portfolio, according to the same overview by TradingView.

For investors, these late-stage studies are crucial because successful trial outcomes can translate into new revenue streams that help stabilize earnings once contributions from older blockbuster drugs moderate.

Stock trades near recent high with solid volume

AbbVie stock closed at USD 261.77 on the NYSE on September 14, 2026, after trading in a range between USD 260.10 and USD 264.65 during that session, with a prior close at USD 257.12 and a daily gain of 1.81 percent, as shown by price data compiled in an overview on Investing.com for the period up to September 15, 2026 and by a stock-price table on Forbes.

The same data sets indicate that the trading volume on September 14, 2026 reached about 4.36 million shares, reflecting continued investor interest as the stock trades close to previous highs, according to Forbes.

In a recent session assessed by another research note, AbbVie shares closed at USD 261.70, marking a 1.78 percent gain and outperforming the S&P 500, which fell 0.48 percent over the same period, as highlighted by Zacks on September 14, 2026.

Valuation and key risk factors

Despite the favorable dividend and earnings backdrop, valuation is becoming a more prominent topic: AbbVie’s price-to-earnings and price-to-sales ratios stand above their five-year averages, suggesting the stock is less likely to appeal to strict value investors at current levels, according to Yahoo Finance.

One of the main longer-term risk factors for AbbVie remains the evolution of its product portfolio as legacy franchises face competitive pressures and patent expirations, while newer drugs must deliver sufficient growth to maintain the current revenue trajectory and support ongoing dividend payments.

In addition, macroeconomic and regulatory developments in key markets such as the United States and Europe can influence pricing dynamics and reimbursement conditions for AbbVie’s therapies, adding another layer of uncertainty to future cash flows that investors monitor closely when assessing the stock.

AbbVie Inc. stock price as of the last trading day

As of September 14, 2026, AbbVie Inc. stock closed at USD 261.77 on the NYSE, near the top of its recent trading range and supported by robust trading volume, providing investors with a reference level as they weigh the company’s strengthened dividend, double-digit revenue growth and supportive analyst sentiment.